Stock 601607 SHANGHAI PHARMACEUTICALS HOLDING CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shanghai Pharmaceuticals Holding Co., Ltd

Equities

601607

CNE000000C82

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
17.85 CNY +0.22% Intraday chart for Shanghai Pharmaceuticals Holding Co., Ltd +0.34% +6.69%
Apr. 26 Shanghai Pharmaceuticals Holding Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 01 Shanghai Pharma's Profit Plunges 33% in 2023 Despite 12% Revenue Growth; Shanghai Shares Rise 4% MT

Strengths

  • The stock, which is currently worth 2024 to 0.29 times its sales, is clearly overvalued in comparison with peers.
  • The company appears to be poorly valued given its net asset value.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The company is highly valued given the cash flows generated by its activity.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+6.69% 8.19B
B
MCKESSON CORPORATION Stock McKesson Corporation
+17.35% 71.39B
C+
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+5.38% 8.59B
C
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-20.96% 7.91B
B-
H. LUNDBECK A/S Stock H. Lundbeck A/S
+0.49% 4.54B
B-
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+17.12% 4.31B
B+
EBOS GROUP LIMITED Stock EBOS Group Limited
-3.38% 3.93B
B-
GALENICA AG Stock Galenica AG
-2.61% 3.86B
B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+22.08% 3.64B
C+
MEDIPAL HOLDINGS CORPORATION Stock MediPal Holdings Corporation
+7.96% 3.29B
C
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 601607 Stock
  4. Ratings Shanghai Pharmaceuticals Holding Co., Ltd